HIGHLIGHTS
SUMMARY
This study reports preclinical data showing that the interleukin (IL)-1b modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1b antibody gevokizumab improves 'surrogate' markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1b modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be Indeed, IL-1b plays an orchestrating role in the inflammatory response to myocardial injury, including enhanced synthesis of other proinflammatory mediators, activation of profibrotic pathways (5), and promotion of cytokine-induced cardiomyocyte apoptosis (9) but also exerts direct negative inotropic effects on myocyte contractility (9-11).
Although the deleterious role of IL-1b in the acute consequences of cardiac I/R injury has been well established (7, 12) , the neutralization and modulation of IL-1b after myocardial infarction in mice has been suggested as a therapeutic target in the prevention of long-term consequences of I/R (i.e., development of heart failure [HF]) (7, 13, 14) . Thus, the aim of this study was to determine the short-and long-term effects of treatment with the IL-1b modulating antibody gevokizumab (15, 16) , initiated either 1 h following reperfusion after myocardial ischemia and continued for 7 (early short-term) or 90 (early long-term) days or initiated 7 days following reperfusion after myocardial ischemia and continued for 83 (delayed long-term) days on I/R-induced LV remodeling or dysfunction and coronary dysfunction. Moreover, as several pathologies, notably diabetes, are known to aggravate myocardial I/R injury, we also evaluated Gevokizumab in the setting of type 2 diabetes, using Goto-Kakisaki (GK) rats.
Our results showed that the IL-1b antibody gevokizumab induces an immediate but sustained improvement of I/R-induced cardiac and coronary dysfunctions in "healthy" as well as diabetic rat models. However, whether IL-1b modulation may be a therapeutic option for the acute and long-term consequences (i.e., survival of cardiac I/R in humans remains to be determined).
MATERIALS AND METHODS
The investigation conforms to the Guide for the Care In sham-operated GK rats, the acetylcholineinduced coronary relaxation was impaired compared Harouki et al. Harouki et al.
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with that in sham-operated animals. Two-day gevokizumab reduced catalase activity and tended to normalize mitochondrial SOD ( Table 3 ). 
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weight nor collagen accumulation were modified by short-term gevokizumab initiated in a context of established HF, but myocardial tissue perfusion of the "viable" part of the LV was increased ( Table 4) Abbreviations as in Table 1 .
Harouki et al. Values are mean AE SD. *p < 0.05 versus untreated I/R.
Abbreviations as in Table 1 . (12, 51) . However, it must be stressed that, in this experimental study, the duration of the ischemic period is longer in nondiabetic animals in order to reproduce similar I/R injury since diabetes renders prone to I/R injury.
However, in the clinical setting diabetic patients will have similar time of ischemia to nondiabetic patients, which could limit the efficacy of gevokizumab in humans. These critical points needs to be evaluated in humans.
It must be stressed that several pathologies, such as diabetes, render the heart more prone to I/R injury, which may be related in part to the modest but TRANSLATIONAL OUTLOOK: However, whether IL1b modulation per se or in combination with standard treatments for HF improves long-term outcome in human HF remains to be determined.
